Ticker Hub
VNDA — AI Analysis & Sentiment
3 recent AI-generated analyses for VNDA. Sentiment and confidence insights updated continuously.
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
Vanda's orphan drug designation in Japan is a material positive for its pipeline, granting exclusivity and development support. This regulatory de-...
May 27, 2026Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Vanda's publication of positive Phase III clinical data for Imsidolimab in NEJM Evidence strengthens its BLA for GPP, increasing the likelihood of ...
Apr 28, 2026Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
Vanda Pharmaceuticals announced that the FDA granted a hearing for HETLIOZ® regarding its use in jet lag disorder. This is significant as it marks ...
Mar 3, 2026